Cancer Research Targets  Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mitchell, M. S.
Right arrow Articles by Deans, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mitchell, M. S.
Right arrow Articles by Deans, R. J.
[Cancer Research 60, 6448-6456, November 15, 2000]
© 2000 American Association for Cancer Research


Immunology

A Novel Melanoma Gene (MG50) Encoding the Interleukin 1 Receptor Antagonist and Six Epitopes Recognized by Human Cytolytic T Lymphocytes1

Malcolm S. Mitchell2, June Kan-Mitchell, Boris Minev, Carl Edman and Robert J. Deans

Center for Biological Therapy and Melanoma Research, University of California, San Diego, La Jolla, California 92093, and the University of Southern California-Norris Cancer Center, University of Southern California, Los Angeles, California 90025

We identified a novel 8.1-kb human melanoma gene, MG50, derived from subtractive hybridization with a squamous lung carcinoma cell line, LU-1. 6.8 kb containing an open reading frame were sequenced, and the structure of the encoded 1496 amino acid protein was deduced. With HLA-A2.1-transduced Drosophila cells as antigen-presenting cells, we identified six epitopes restricted by HLA-A2.1 that elicited CTLs in vitro. Reactivity of the CTLs to melanoma cells containing MG50 indicated that the epitopes were displayed naturally. Significant cross-reactivity of CTLs immunized against a melanoma cell line that lacked HLA-A2.1 indicated that at least four of the epitopes were also recognized in a different HLA class I context, most likely HLA-A*6802. By quantitative reverse transcription, MG50 message was found in one of two skin melanoma cell lines, an ocular melanoma cell line, two of four metastatic skin melanomas, two of three mammary carcinomas, one of two colon carcinomas, and an ovarian carcinoma. Of six normal tissues, MG50 was found only in a specimen of normal skin and was absent from a congenital nevus. It is likely that MG50 is the gene for the interleukin 1 receptor antagonist because a reported sequence of cDNA from the latter had a sequence of 528 bases in the 3' region, a long contiguous base sequence, and 176 encoded amino acids identical with those of MG50. MG50 is one of the few melanoma-associated antigens that is not a differentiation antigen or a mutated protein. Because of its nature, it may prove to be important in the pathogenesis of the tumors in which it is found, as well as an immunogen and target for immunotherapy.




This article has been cited by other articles:


Home page
JCOHome page
M. S. Mitchell, J. Abrams, J. A. Thompson, M. Kashani-Sabet, R. C. DeConti, W.-J. Hwu, M. B. Atkins, E. Whitman, M. S. Ernstoff, F. G. Haluska, et al.
Randomized Trial of an Allogeneic Melanoma Lysate Vaccine With Low-Dose Interferon Alfa-2b Compared With High-Dose Interferon Alfa-2b for Resected Stage III Cutaneous Melanoma
J. Clin. Oncol., May 20, 2007; 25(15): 2078 - 2085.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. ProteomicsHome page
V. Castronovo, D. Waltregny, P. Kischel, C. Roesli, G. Elia, J.-N. Rybak, and D. Neri
A Chemical Proteomics Approach for the Identification of Accessible Antigens Expressed in Human Kidney Cancer
Mol. Cell. Proteomics, November 1, 2006; 5(11): 2083 - 2091.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
S. L. Madden, B. P. Cook, M. Nacht, W. D. Weber, M. R. Callahan, Y. Jiang, M. R. Dufault, X. Zhang, W. Zhang, J. Walter-Yohrling, et al.
Vascular Gene Expression in Nonneoplastic and Malignant Brain
Am. J. Pathol., August 1, 2004; 165(2): 601 - 608.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. S. Mitchell, J. Kan-Mitchell, P. R. Morrow, D. Darrah, V. E. Jones, and M. F. Mescher
Phase I Trial of Large Multivalent Immunogen Derived from Melanoma Lysates in Patients with Disseminated Melanoma
Clin. Cancer Res., January 1, 2004; 10(1): 76 - 83.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
S. E. Bell, A. Mavila, R. Salazar, K. J. Bayless, S. Kanagala, S. A. Maxwell, and G. E. Davis
Differential gene expression during capillary morphogenesis in 3D collagen matrices: regulated expression of genes involved in basement membrane matrix assembly, cell cycle progression, cellular differentiation and G-protein signaling
J. Cell Sci., January 8, 2001; 114(15): 2755 - 2773.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.